A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.
From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.
This is an NIH-funded study which will estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. We are developing model scenarios based on input from country stakeholders, including national TB program and immunization program officials.
Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.
This is a study funded by the American Lung Association which will explore the potential impact of targeted implementation of a prevention of disease vaccine in a low TB burden country, the U.S.A.
This project aims to collect data to: 1) Assess health facility and health systems readiness for a new TB vaccine, and 2) Explore decision-making factors for new TB vaccine demand and acceptance
This paper synthesizes the insights and lessons learned from different vaccine introductions among adult populations in LMICs from the last decade (i.e., 2013 to 2023).